Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome

NCT02187250 Phase 4 COMPLETED

The purpose of this study was to determine whether monotherapy treatment with phosphodiesterase-4 (PDE-4) inhibitor roflumilast is more effective than treatment with glucagon-like protein 1 (GLP-1) liraglutide or treatment with metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (PCOS) regarding weight reduction who have not been treated before. The investigators anticipated greater changes in body weight in patients on roflumilast treatment than in liraglutide or metformin.

Details

Lead sponsor	University Medical Centre Ljubljana
Phase	Phase 4
Status	COMPLETED
Enrolment	45
Start date	2014-03
Completion	2014-06

Conditions

• PCOS
• Obesity

Interventions

• metformin
• liraglutide
• roflumilast

Primary outcomes

• The main outcome was change in body weight. — Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial.
  The patient's body weight was measured in kilograms.

Countries

Slovenia